Antiproliferative effect of GTS-21 in glioblastoma cells.
3-(2,4-dimethoxybenzylidene) anabaseine
acetylcholine receptors
bungarotoxin
glioblastoma
nicotine receptors
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
28
02
2021
accepted:
22
07
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is the most common malignant brain tumour in adults. The poor prognosis and short median overall survival of patients with GBM is associated with resistance to therapy after surgical and adjuvant treatment. The expression of various acetylcholine receptors (AChR) in GBM has been widely reported. The present study aimed to investigate the expression of cholinergic system-related genes in primary GBM and to explore the antiproliferative effect of 3-(2,4-dimethoxybenzylidene) anabaseine (GTS-21) in GBM cell lines. Therefore, the expression of 28 genes associated with the cholinergic system was detected using a customized RT
Identifiants
pubmed: 34539863
doi: 10.3892/ol.2021.13020
pii: OL-0-0-13020
pmc: PMC8436335
doi:
Types de publication
Journal Article
Langues
eng
Pagination
759Informations de copyright
Copyright © 2021, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Anticancer Res. 2016 Mar;36(3):887-97
pubmed: 26976975
Cancer Res. 2011 Jun 15;71(12):4055-60
pubmed: 21628493
Oncotarget. 2016 Jan 5;7(1):459-72
pubmed: 26575950
Trends Mol Med. 2009 Nov;15(11):519-30
pubmed: 19889578
Genome Biol. 2003;4(8):R50
pubmed: 12914658
Nat Neurosci. 2014 Jul;17(7):934-42
pubmed: 24880216
Pharmacol Res. 2021 Jan;163:105336
pubmed: 33276105
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
J Med Chem. 2018 Dec 13;61(23):10531-10544
pubmed: 30403486
Genes Dev. 2001 Jun 1;15(11):1311-33
pubmed: 11390353
Biochem Pharmacol. 2011 Oct 15;82(8):904-14
pubmed: 21718690
Genomics. 1998 Sep 1;52(2):173-85
pubmed: 9782083
Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):105-112
pubmed: 30657552
Br J Pharmacol. 2008 Aug;154(8):1558-71
pubmed: 18500366
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Brain. 2007 Oct;130(Pt 10):2596-606
pubmed: 17785346
J Intern Med. 2009 Jun;265(6):663-79
pubmed: 19493060
Neuroscience. 1987 Aug;22(2):381-94
pubmed: 2823172
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32817393
J Neurochem. 2004 Apr;89(2):337-43
pubmed: 15056277
J Biol Chem. 2011 Jan 7;286(1):594-606
pubmed: 21047781
Int J Mol Sci. 2012;13(2):2219-38
pubmed: 22408449
Cancer Microenviron. 2018 Jun;11(1):1-11
pubmed: 29502307
Neuropharmacology. 2015 Sep;96(Pt B):274-88
pubmed: 25701707
Brain Behav Immun. 2005 Nov;19(6):493-9
pubmed: 15922555